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e24 -Case ReportUse of Denosumab for Renal Cell
Carcinoma-Associated Malignant Hypercalcemia:
A Case Report and Review of the Literature
Ashley Freeman,1 Joelle El-Amm,2 Jeanny B. Aragon-Ching2Clinical Practice Points
 Hypercalcemia is a common problem in patients with
renal cell carcinoma.
 The standard treatment for malignant hypercalcemia
includes bisphosphonates, hydration, and calcitonin.
 Denosumab is approved for the prevention of skeletal-
related events in patients with metastatic solid tumors.
 The main side effect of denosumab is hypocalcemia.
 Denosumab presents as an attractive option for
treatment of malignant hypercalcemia.
 Denosumab is less nephrotoxic than bisphospho-
nates and could be an alternative option for treatment
of malignant hypercalcemia in renal failure.Clinical Genitourinary Cancer, Vol. 11, No. 4, e24-6 ª 2013 Elsevier Inc. All rights reserved.
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Renal cell carcinomaIntroduction
Malignant hypercalcemia develops as a late complication of
cancers and often portends a poor prognosis.1 We present a case of
bisphosphonate-refractory malignant hypercalcemia secondary to
renal cell carcinoma successfully managed with denosumab and
herein review the literature supporting the potential use of deno-
sumab for treatment of malignant hypercalcemia.
Case Presentation
A 66-year-old man with newly diagnosed metastatic renal cell
carcinoma presented to the emergency department with altered
mental status, lethargy, constipation, and polyuria. His physical
examination was notable for generalized weakness and drowsiness.
Laboratory studies revealed hypercalcemia (corrected calcium 16
mg/dL), hyponatremia (sodium 118 mmol/L), acute kidney injury
(creatinine 2.9 mg/dL), and a contraction metabolic alkalosis
(bicarbonate 32.2 mmol/L). Metastatic renal cell carcinoma had
been diagnosed 1 month earlier after he presented with persistent1Department of Medicine
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Clinical Genitourinary Cancer December 2013back pain. Computed tomography (CT) scan of the chest,
abdomen, and pelvis showed a right renal mass measuring 4.0 
3.3  3.4 cm and a left chest wall mass originating from the
seventh rib with a focal lytic lesion in the left eighth rib and direct
extension and destruction of the left sixth rib. Magnetic resonance
imaging of the spine demonstrated T3-T7 metastatic lesions with
epidural extension into the central canal. Biopsy of the chest wall
mass revealed high-grade carcinoma with epithelial and spindle
cell differentiation and sarcomatoid morphology (illustration not
shown).
The patient was admitted to the intensive care unit for man-
agement of severe hypercalcemia. He was treated with intravenous
ﬂuids, calcitonin, and pamidronate. Calcium levels along with other
metabolic abnormalities corrected quickly. A CT scan was repeated
during his admission and showed multilevel osteolytic lesions from
T2 to T8 with a large associated soft tissue component at T5 and
T6 in the spinal canal, causing cord compression (Fig. 1). The
patient underwent debulking surgery and laminectomy of T5 to T7.
Pathology from thoracic vertebral specimens showed predominant
clear cell renal cell cancer histology (Fig. 2). Radiation therapy to
the thoracic spine was started and he was prescribed at discharge
etidronate 400 mg daily for prevention of hypercalcemia.
At a follow-up visit 2 weeks after discharge, the patient was again
noted to be lethargic and confused. Corrected calcium at this time
was 15.8 mg/dL, parathyroid hormone (PTH)-related peptide
(rp) was elevated at 4.1 pmol/L with an appropriately depressed
intact PTH (< 3 pg/mL). He was again admitted to the hospital1558-7673/$ - see frontmatter ª 2013 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.clgc.2013.06.002
Figure 1 Computed Tomography Scan of the Thoracic Spine Showed Multiple Bone Metastases and Evidence of Cord Compression at
the Level of T5 to T6
Figure 2 Pathology Findings. Pathology of the Resected Thoracic Spinal Mass Tumor was Consistent With Metastatic Renal Cell
Carcinoma, Clear Cell Type, Using Hematoxylin and Eosin Stain (A). The Tumor Cells Were Immunoreactive With Clusters of
Differentiation 10 (B), MAK 6 (C), and Vimentin (D)where he received intravenous ﬂuids and pamidronate. Because
bisphosphonate therapy was not sufﬁcient to maintain normal
calcium levels, he was started on subcutaneous denosumab 120 mg
every 4 weeks. Two weeks after receiving the ﬁrst dose of denosumab,
the patient’s calcium level normalized and has been maintained for
more than 10 months.After stabilization of the patient’s calcium levels, systemic
chemotherapy for metastatic renal cell carcinoma with sarcomatoid
features was begun, using gemcitabine 1000 mg/m2 on days 1 and 8
and sunitinib 37.5 mg on days 1 to 14 every 21 days. He continues
to receive subcutaneous denosumab 120 mg every 4 weeks and his
calcium level remained normal at the time of reporting.Clinical Genitourinary Cancer December 2013 - e25
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e26 -Discussion
Hypercalcemia of malignancy complicates approximately 15% of
cases of renal cell carcinoma and confers a grave prognosis.2
Mechanisms of hypercalcemia in the setting of renal cell carci-
noma include osteolytic bone metastases, tumor secretion of PTHrp
and production or activation of calcitriol.3 The extensive osteolytic
bone metastases and elevated PTHrp exhibited by our patient
contributed to severe hypercalcemia. Circulating tumor-derived
factors such as PTHrp and other humoral local factors secreted
from metastatic cells drive the receptor activator of nuclear factor
kappa-B ligand (RANKL)-mediated osteoclast activation and bone
resorption. The resulting osteolysis causes release of bone-derived
growth factors, which in turn promotes cancer cell proliferation
and further PTHrp production via transforming growth factor-beta
and mitogen-activated protein kinase pathways.
Treatment of hypercalcemia of malignancy is based on increasing
urinary excretion of calcium or inhibition of osteoclastic bone
resorption via RANKL or PTHrp inhibition.4 Apart from using
aggressive hydration and diuresis when volume repletion is achieved,5
bisphosphonates, which are incorporated into osteoclasts, thereby
inhibiting function and promoting apoptosis, are currently the main-
stay of treatment for hypercalcemia of malignancy.6 In this case, we
were unable to maintain normal calcium levels with bisphosphonate
use alone. Denosumab is a human monoclonal antibody against
RANKL, which results in a reduced rate of bone resorption through
inhibition of osteoclast maturation, activation, and function.7
Denosumab is currently approved by the US Food and Drug
Administration for treatment of bone metastases from solid tumors
and has been shown to delay skeletal-related events.8,9 The main
adverse effect of denosumab use is hypocalcemia, which occurs at a
rate of approximately 5% to 13% compared with 1% to 6% with
bisphosphonate use.10-12 Hu et al conducted a clinical trial on the
use of denosumab speciﬁcally for treatment of bisphosphonate-
refractory hypercalcemia of malignancy.13 Patients with solid tu-
mors or multiple myeloma that had persistently elevated calcium
levels (> 12.5 mg/dL) despite use of intravenous bisphosphonate
therapy received denosumab 120 mg subcutaneously every 4 weeks
with additional doses of 120 mg on days 8 and 15 during the ﬁrst
month. Interim analysis showed that 80% of participants had a
response (Ca < 11.5 mg/dL) within the ﬁrst 10 days. Additionally,
pooled analyses showed that denosumab also delayed the onset of
hypercalcemia in patients receiving this medication for bone me-
tastases when compared with patients taking zoledronic acid.14
Denosumab is cleared by the reticuloendothelial system, which
makes it an attractive option in patients with renal failure in whom
bisphosphonates are relatively contraindicated. In fact, in clinical
trials comparing bisphosphonates with denosumab, in patients with
cancer whose creatinine clearance was less than 60 mL/min, dete-
rioration of renal function was observed in 20% to 22% of patientsClinical Genitourinary Cancer December 2013treated with bisphosphonates compared with 6% to 11% of patients
treated with denosumab.9,11
Conclusion
Denosumab has been approved for the indication of delaying
skeletal-related events in solid tumors metastatic to bone. This drug
is well tolerated with the main side effect being hypocalcemia. This
property makes denosumab a viable option for treatment of ma-
lignant hypercalcemia that might not necessarily be associated with
bony metastases.15 Currently, there is an ongoing clinical trial
studying the use of denosumab for refractory malignancy-associated
hypercalcemia and the results are eagerly awaited.16
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